• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ImmunityBio, Inc. - Common Stock (NQ:IBRX)

    2.280 -0.020 (-0.87%)
    Streaming Delayed Price Updated: 1:31 PM EST, Dec 5, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,789,372
    Open 2.310
    Bid (Size) 2.270 (11,900)
    Ask (Size) 2.280 (13,300)
    Prev. Close 2.300
    Today's Range 2.243 - 2.320
    52wk Range 1.830 - 5.120
    Shares Outstanding 391,156,513
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know ↗
    A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline. 
    Via The Motley Fool

    Performance

    YTD
    -11.3%
    -11.3%
    1 Month
    +9.6%
    +9.6%
    3 Month
    -4.6%
    -4.6%
    6 Month
    -21.4%
    -21.4%
    1 Year
    -51.9%
    -51.9%

    More News

    Read More
    News headline image
    Heights Capital Walks From Archer Aviation: What It Means for Investors ↗
    Via The Motley Fool
    ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals ↗
    Via Stocktwits
    News headline image
    Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean. ↗
    Via The Motley Fool
    News headline image
    New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗
    Via Benzinga
    News headline image
    Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
    Via MarketBeat
    Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts ↗
    Via Stocktwits
    News headline image
    ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    What's Going On With ImmunityBio Shares Tuesday? ↗
    Via Benzinga
    News headline image
    Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    IBRX Sales Soar 2,540% ↗
    Via The Motley Fool
    News headline image
    ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper ↗
    Via Benzinga
    Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
    Via Investor Brand Network
    News headline image
    Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
    Via FinancialNewsMedia
    Topics Death
    News headline image
    UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
    From ImmunityBio, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is ImmunityBio, Inc. - Common Stock publicly traded?
    Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
    What exchange does ImmunityBio, Inc. - Common Stock trade on?
    ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
    The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
    What is the current price of ImmunityBio, Inc. - Common Stock?
    The current price of ImmunityBio, Inc. - Common Stock is 2.280
    When was ImmunityBio, Inc. - Common Stock last traded?
    The last trade of ImmunityBio, Inc. - Common Stock was at 12/05/25 01:31 PM ET
    What is the market capitalization of ImmunityBio, Inc. - Common Stock?
    The market capitalization of ImmunityBio, Inc. - Common Stock is 891.84M
    How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
    ImmunityBio, Inc. - Common Stock has 892M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.